Eli Lilly
- Collected applications
- 9
- Share of collected applications with IPC
- 0.6%
Coverage is incomplete; counts and shares describe only the collected subset.
View Eli Lilly publications in this fieldCompany patentsCompare
HEAD TO HEAD
Eli LillyKweichow MoutaiNVIDIA
Technology portfolios compared in the same window and counting units. Scale is compared only within the same field or subclass.
+ Agricultural Bank of China2025-01 — 2025-12+ Alibaba2025-01 — 2025-12+ Alphabet (Google)2025-01 — 2025-12+ Amazon2025-01 — 2025-12+ Apple2025-01 — 2025-12+ Bank of China2025-01 — 2025-12+ BOE2024-01 — 2024-12+ Broadcom2025-01 — 2025-12+ BYD2024-01 — 2024-12+ CATL2024-01 — 2024-12+ China Construction Bank2025-01 — 2025-12+ China Mobile2025-01 — 2025-12+ CXMT2025-01 — 2025-12✓ Eli Lilly2025-01 — 2025-12+ Huawei2024-01 — 2024-12+ ICBC2025-01 — 2025-12+ Meta2025-01 — 2025-12+ Microsoft2025-01 — 2025-12+ Midea2024-01 — 2024-12✓ Kweichow Moutai2025-01 — 2025-12✓ NVIDIA2025-01 — 2025-12+ PetroChina2025-01 — 2025-12+ SpaceX2025-01 — 2025-12+ Tencent2025-01 — 2025-12+ Tesla2025-01 — 2025-12
Same window · published 2025-01-01 — 2025-12-31Some name or date coverage is incomplete; affected counts are lower bounds
This is a structural comparison of collected portfolios. The same requested window does not establish equal entity scope, covered months or industry; no competitive ranking is inferred.
Applicant-name coverage differs. The counts below cover only the listed names and do not represent complete company portfolios.
Eli Lilly: Applicant names included in these statistics — ELI LILLY AND CO · ELI LILLY AND COMPANY USA · LILLY CO ELIReviewed names not covered — ELI LILLY AND COMPANY
Kweichow Moutai: Applicant names included in these statistics — KWEICHOW MOUTAI CO LTDReviewed names not covered — KWEICHOW MOUTAI CO., LTD. · 贵州茅台酒股份有限公司
NVIDIA: Applicant names included in these statistics — NVIDIA CORPReviewed names not covered — NVIDIA CORP. · NVIDIA CORPORATION
Eli Lilly
- Publications
- 1,602
- Invention share
- 45%
- Concentration
- 0.73
- Green technology
- —
Kweichow Moutai
- Publications
- 83
- Invention share
- 71%
- Concentration
- 0.28
- Green technology
- —
NVIDIA
- Publications
- 2,387
- Invention share
- 81%
- Concentration
- 0.66
- Green technology
- —
0.26
Eli Lilly × Kweichow Moutai
0.01
Eli Lilly × NVIDIA
0.50
Kweichow Moutai × NVIDIA
01Technology field mirror
The 12 fields with the largest combined share. Share shows structure; count shows scale.
| Technology field | Eli Lilly / Kweichow Moutai / NVIDIA |
|---|---|
| Computer technology | 0.6% 24.1% 79.3% |
| Pharmaceuticals | 68.5% 0% 0% |
| Biotechnology | 39.9% 24.1% 0% |
| Measurement | 1% 30.1% 7% |
| Organic fine chemistry | 25.8% 2.4% 0% |
| Medical technology | 17.6% 3.6% 0.5% |
| Food chemistry | 0.2% 18.1% 0% |
| Analysis of biological materials | 1.7% 13.3% 0% |
| Handling | 0.2% 9.6% 2.6% |
| Digital communication | 0.1% 0% 9.1% |
| Audio-visual technology | 0.1% 0% 8.8% |
| Environmental technology | 0% 7.2% 0% |
Inspect one technology field
Inspect collected applications, portfolio share and supporting publications within one field. A technology overlap does not establish that companies in different industries are direct competitors.
Kweichow Moutai
- Collected applications
- 20
- Share of collected applications with IPC
- 24.1%
Coverage is incomplete; counts and shares describe only the collected subset.
View Kweichow Moutai publications in this fieldNVIDIA
- Collected applications
- 1,858
- Share of collected applications with IPC
- 79.3%
Coverage is incomplete; counts and shares describe only the collected subset.
View NVIDIA publications in this fieldOne application may belong to multiple fields, so shares can sum to more than 100%. Drill-down lists publications; an application publication and its grant may appear separately.
02Same problem: shared IPC subclasses
The 10 subclasses in every company's top 60 with the most combined applications. Scale is compared within a subclass, never across different business scopes.
G06FData processing
Eli Lilly2
Kweichow Moutai15
NVIDIA881
G06NComputing models, AI
Eli Lilly3
Kweichow Moutai5
NVIDIA497
G06VImage and video recognition
Eli Lilly2
Kweichow Moutai4
NVIDIA403
G01NAnalysing materials
Eli Lilly32
Kweichow Moutai25
NVIDIA3
A61BMedical diagnosis
Eli Lilly36
Kweichow Moutai3
NVIDIA5
G06QBusiness data processing
Eli Lilly3
Kweichow Moutai2
NVIDIA12
G01DGeneral measuring
Eli Lilly2
Kweichow Moutai4
NVIDIA3
03Where each one leans
Observed emphasis within each company’s collected top-60 IPC subclasses. A dash for another company means outside its top-60 list, not zero applications or a market gap. Incomplete coverage can also change the ordering.
Eli Lilly
- A61K
- Eli Lilly
- 926
- Kweichow Moutai
- 1
- NVIDIA
- —
- A61P
- Eli Lilly
- 766
- Kweichow Moutai
- —
- NVIDIA
- —
- C07K
- Eli Lilly
- 454
- Kweichow Moutai
- —
- NVIDIA
- —
- C07DHeterocyclic compounds
- Eli Lilly
- 300
- Kweichow Moutai
- —
- NVIDIA
- —
- A61M
- Eli Lilly
- 196
- Kweichow Moutai
- —
- NVIDIA
- —
- C07C
- Eli Lilly
- 34
- Kweichow Moutai
- —
- NVIDIA
- —
Kweichow Moutai
- G01NAnalysing materials
- Eli Lilly
- 32
- Kweichow Moutai
- 25
- NVIDIA
- 3
- C12G
- Eli Lilly
- —
- Kweichow Moutai
- 10
- NVIDIA
- —
- C12R
- Eli Lilly
- 1
- Kweichow Moutai
- 10
- NVIDIA
- —
- C12QBiochemical testing
- Eli Lilly
- 12
- Kweichow Moutai
- 9
- NVIDIA
- —
- C12NMicroorganisms, enzymes
- Eli Lilly
- 153
- Kweichow Moutai
- 16
- NVIDIA
- —
- G16B
- Eli Lilly
- —
- Kweichow Moutai
- 6
- NVIDIA
- 4
NVIDIA
- G06TImage processing
- Eli Lilly
- 5
- Kweichow Moutai
- —
- NVIDIA
- 719
- G06FData processing
- Eli Lilly
- 2
- Kweichow Moutai
- 15
- NVIDIA
- 881
- G06NComputing models, AI
- Eli Lilly
- 3
- Kweichow Moutai
- 5
- NVIDIA
- 497
- G06VImage and video recognition
- Eli Lilly
- 2
- Kweichow Moutai
- 4
- NVIDIA
- 403
- H04LDigital transmission
- Eli Lilly
- —
- Kweichow Moutai
- —
- NVIDIA
- 155
- B60WVehicle sub-unit control
- Eli Lilly
- —
- Kweichow Moutai
- —
- NVIDIA
- 138
04Publication rhythm
| Period | Eli Lilly | Kweichow Moutai | NVIDIA |
|---|---|---|---|
| 2025-01 | ≥118 (partial coverage) | ≥6 (partial coverage) | ≥182 (partial coverage) |
| 2025-02 | ≥121 (partial coverage) | ≥6 (partial coverage) | ≥166 (partial coverage) |
| 2025-03 | ≥158 (partial coverage) | ≥7 (partial coverage) | ≥170 (partial coverage) |
| 2025-04 | ≥110 (partial coverage) | ≥2 (partial coverage) | ≥158 (partial coverage) |
| 2025-05 | ≥134 (partial coverage) | ≥7 (partial coverage) | ≥193 (partial coverage) |
| 2025-06 | ≥140 (partial coverage) | ≥5 (partial coverage) | ≥183 (partial coverage) |
| 2025-07 | ≥138 (partial coverage) | ≥5 (partial coverage) | ≥243 (partial coverage) |
| 2025-08 | ≥134 (partial coverage) | ≥4 (partial coverage) | ≥182 (partial coverage) |
| 2025-09 | ≥132 (partial coverage) | ≥11 (partial coverage) | ≥265 (partial coverage) |
| 2025-10 | ≥155 (partial coverage) | ≥10 (partial coverage) | ≥234 (partial coverage) |
| 2025-11 | ≥140 (partial coverage) | ≥10 (partial coverage) | ≥199 (partial coverage) |
| 2025-12 | ≥122 (partial coverage) | ≥10 (partial coverage) | ≥212 (partial coverage) |
Empty dashed outlines mark uncollected periods. Hatched bars and ≥ counts mark partial coverage.
Publication timing follows examination and publication cycles, not R&D intensity.
What makes it comparableThe same publication window and counting units. Companies with different windows are not put in one comparison.
What is not comparableGroup totals. Business and entity scopes differ; compare scale within a field or subclass.
Not a rankingSimilarity and shares describe structure, not patent value, quality or technical leadership.